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INTRODUCTION
With the ability to enrich for rare populations of cells using cell sorting techniques and the development of appropriate xenotransplant models, it has been possible to prospectively characterize the surface antigen phenotype of both normal and leukemic stem cell populations from normal and AML specimens. A number of lines of evidence have demonstrated that human HSC are contained in the Lin-CD34+CD38-fraction of hematopoietic progenitors (1, 2) . Additional studies have demonstrated that human HSC also express CD90 (3) (4) (5) . Perhaps the best demonstration of HSC function comes from human clinical trials of autologous mobilized peripheral blood in clinical transplantation, where long-term engraftment was provided by transplantation of purified CD34+CD90+ cells (6) (7) (8) . In multiple published reports, a common phenotype for AML LSC has been identified and found to be negative for expression of lineage markers (Lin-), positive for expression of CD34, and negative for expression of CD38 (9) (10) (11) . These Lin-CD34+CD38-LSC were further shown to be positive for expression of IL-3Rα (CD123) and negative for expression of CD90 (Thy-1) (12) (13) (14) .
The cancer stem cell model has significant implications for the design of therapies for AML as well as other cancers. It postulates that in order to eradicate the tumor, therapies must target and eliminate the cancer stem cells. For the development of such cancer stem cell-targeted therapies, it is necessary to identify molecules and pathways that are preferentially expressed in these cancer stem cells compared to their normal counterparts.
DNA microarray technology has proven to be a powerful tool for the large scale analysis of gene expression differences, particularly in cancer investigations (15) . There are many published reports of gene expression profiles of bulk human AML samples, including several very large cohorts (16) (17) (18) . However, few studies have directly compared AML to normal hematopoietic cells (19) . Comparisons of unfractionated populations may fail to identify critical differentially expressed genes and pathways within infrequent LSC and rare HSC populations. One report has investigated gene expression differences between LSC and non-LSC from the same AML samples in order to identify genes critical to LSC function; however, no direct comparison was made to normal HSC (20). An additional study has investigated gene expression differences between normal HSC and HSC from patients with 5q-myelodysplastic syndrome, and identified genes potentially involved in the pathogenesis of this disorder (21). We report the first analysis of gene expression differences between AML LSC and normal bone marrow HSC using two independently derived data sets. We have applied the gene sets to a systems level pathway analysis and have identified molecular pathways and networks that are dysregulated between AML LSC and HSC.
RESULTS

Generation of gene expression profiles of human HSC and AML LSC
Two independent sets of microarray gene expression profiles of human bone marrow HSC and AML LSC were generated at the University of Michigan (n=3 HSC, n=7 AML) and Stanford University (n=4 HSC, n=9 AML) by fluorescence-activated cell sorting (FACS) of patient samples, followed by RNA purification, amplification, and hybridization to Affymetrix oligonucleotide-based microarrays. The clinical features of the AML samples are presented in Supplemental Table 1 , and cover a range of subtypes of AML. These data sets were then combined for the bioinformatic analysis of differentially regulated pathways.
Dysregulated pathways between AML LSC and HSC
Although LSC and normal HSC share the common characteristics of unlimited self-renewal and multi-lineage differentiation, understanding how they differ from each other should reveal fundamental mechanisms governing leukemic transformation. While differentially expressed genes between LSC and HSC can be identified and validated individually, the full potential of genome-wide microarray analysis can be better realized in terms of gene regulatory networks, given that those genes, and the proteins they encode for, function in the context of intertwining pathways. We conducted an unbiased systems level pathway analysis without excluding any genes through a priori gene expression thresholds, by employing a newly developed algorithm dubbed integrative microarray analysis of pathways (IMAP) (22). This analysis first combines microarray data from multiple independent experiments through meta-analysis; a score for each pathway is assigned without specific gene expression cut-offs; the significance of each pathway is then computed by running 1 million iterations of randomly sampled genes.
We used the pathway information from Biocarta (http://www.biocarta.com), KEGG (http://www.genome.jp/kegg/), GeneGo (http://www.genego.com/), and Pathway Studio (http://www.ariadnegenomics.com/products/pathway-studio/) databases as references to derive the top dysregulated pathways. As shown in Table 1 
Validation of top dysregulated pathways using functional groups enrichment analysis
Independent of the IMAP analysis, which takes into account all the genes in a given pathway, we conducted a parallel analysis employing only differentially expressed genes (DEGs) from the combined datasets. The two AML microarray data sets were first combined as described above using z-scores. With p<0.05 we obtained 3005 DEGs (Supplemental Table 3 ). A heat map illustrating the expression of these genes across the Stanford samples is shown in Supplemental Figure 1 . A functional enrichment analysis using this set of genes was performed using the DAVID program (the Database The first data set was generated from sorted leukemic stem cells (LSC) from 7 AML patients and normal hematopoietic stem cells (HSC) from 3 normal controls. The second data set was generated similarly from 9 AML patients and 4 normal individuals.
We obtained 3005 differentially expressed genes with 1451 genes being up regulated and 1554 genes being down regulated in LSC when compared to normal HSC. Many of these genes have been previously identified as being playing a key role in normal stem cell biology as well as in leukemia. Despite the use of different microarray platforms, a detailed analysis of the two independently derived datasets demonstrated a significant degree of overlap between the gene signatures for the two cell types examined.
In addition to providing a genome wide survey for genes whose expression is disrupted in leukemic transformation at the level of the stem cell compartment, a comprehensive, unbiased pathway analysis has allowed the identification of critical pathways which are dysregulated in LSC in comparison to normal HSC. Again, focusing on the difference between normal and leukemic as opposed to stem cell versus progenitor has allowed us to screen out many of the pathways that are involved in stem cell function which are not dysregulated in the leukemic state. Hence, the limited number of pathways we identified as being dysregulated. Furthermore, the significant degree of overlap within and between the different pathway tools utilized suggests that these pathways are critical in the evolution of cancer stem cells from their normal counterparts.
To validate the data sets used, we performed an analysis employing only the 3005 differentially expressed genes (DEGs) from the combined datasets using the DAVID program. This independent and parallel analysis demonstrated a significant degree of overlap with the unbiased pathway analysis and confirmed the validity of the datasets employed in these analyses using a system wide approach.
Many of the pathways we identified as being aberrantly regulated in the LSC from Table 2 ).
The adherens junction has been demonstrated to be critical in the interaction of 
MATERIALS AND METHODS
Human Samples
Normal 
Isolation and Purification of Normal HSC and AML LSC
Viably frozen cells were thawed and resuspended in IMDM with 2% heatinactivated FBS and DNAse I (Sigma). For all normal specimens and leukemic samples with less than 10% of blasts expressing CD34, enrichment was performed prior to staining using CD34 positive selection (Stem Cell Technologies, Canada and Miltenyi Biotech, Germany). Cells were stained as previously described (39) (Supplemental Methods) and analyzed and sorted using FACSAria cytometers (BD Biosciences).
15,000-65,000 normal HSC and approximately 50,000 to 150,000 AML LSC were sorted for RNA purification.
RNA Purification, Amplification, and Microarray Analysis
Total RNA was extracted using Trizol reagent containing either glycogen or linear acrylamide according to the manufacturer's protocol, and then treated with DNaseI 
Integration of Data Set
Since the two data sets of LSC and HSC were obtained from different platforms (3 different chips) and/or different probe sets, the ability to directly compare the data sets to each other was limited, and the correlation coefficient between the two data sets was low. To obtain a statistically more robust data set, we developed a strategy to combine both datasets for an increased sample size ( Figure 1 ).
We performed meta-analysis for integration of the two different microarray data sets using a procedure similar to Setlur et al. (22) . P-values were first calculated for all genes within each data set using the Wilcoxon rank-sum test to compare LSC against HSC samples. These p-values were then mapped onto a standard normal curve. That is, z-scores corresponding to the p-values were obtained by the following conversion:
where p is the p-value to be standardized, μ the mean of all p-values within a data set, and σ the standard deviation of the p-values within the data set. After standardization, the two data sets were integrated to get a weighted z-score for each gene by combining all z-scores for the gene across the two data sets, using the following Liptak-Stouffer formula: where m=2 for this study, i.e. the number of data sets; w i =1, the weight of the i-th data set; z i,g the z-score of gene g in the i-th data set. The less the value of z comb,g , the less the probability of differential expression between HSC and LSC by chance. The probability can be calculated from the cumulative standard normal distribution: 
Dys-regulation of Pathway
To define the dys-regulation of a pathway P, we first assigned a score s g to each gene g in the pathway P by the negative logarithm of its p-value p g , that was
). log( g g p s − =
We then gave a total score S P to the pathway P by summing up all scores of genes in the pathway, namely
To estimate a p-value for significance of this pathway, we iteratively computed similar scores one million times on randomly generated pathways of the same size as that of pathway P.
The frequency of scores which were larger than S P was used as the p-value of pathway P to describe its dys-regulation. For calculation of up-or down-regulated pathways, a positive or negative s g value was used respectively to compute the S p.
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